With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in...
Novo-Nordisk A/S (NVO) has a valuation score of 55/100 (moderate), profitability score of 87/100 (strong), financial health score of 61/100 (moderate), Piotroski F-Score of 3/9, Altman Z-Score of 2.10 (grey zone), revenue growth of +20.4% YoY.
Neutral
Analyst Consensus
HoldWall Street consensus estimates — not a PMP forecast · Updated Aug 31, 2026
Analyst Recommendations37 analysts · 2026-08-01
5
8
22
Strong Buy 5Buy 8Hold 22Sell 1Strong Sell 1
Recent Market Moves
See all NVO moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Aug 26 | Regular | $47.12 | -3.18% | -2.12 |
| Aug 25 | Regular | $48.47 | +3.29% | 2.20 |
| Aug 25 | After-hours | $48.55 | +3.47% | 2.31 |
| Aug 6 | Regular | $45.91 | +3.09% | 2.06 |
| Aug 6 | After-hours | $45.94 | +3.17% | 2.11 |